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Summarv We have studied the pharmacokinetics of mitoxantrone in cancer patients. Two regimens were
used: eight women (10 kinetics) received a 10 min i.-. infusion of 12 mg m of mitoxantrone: seven women
(sexen kinetics) received high-dose mitoxantrone associated to high-dose alkvlating agents and underwent
autologous bone marrou- transplantation (BMT). High-dose mitoxantrone was administered according to two
different protocols. The drug was quantified in plasma with an HPLC assav and pharmacokinetic analy-sis was
performed with the APIS software. Mitoxantrone pharmacokinetics were best described by an open tswo- (six
kinetics) or an open three compartment model (11 kinetics). A large interindivual vanrabilitv was observed in
phamacokinetic parameters. In the first group of patients. mean ± s.d. salues of clearance. half-life and total
distribution solume were 21.41 + 14.59 1 h-'. 19.83 23.95 h. 165.89 134.75 1 respectivelv. In the high-dose
group. these values were 21.68 7.30 1 h-'. 50.26 20.62 h. 413.70 194.81 1 respectively. Results showed
that identification through the open 2-compartment model is certainly related to the small number of late
time-points. We therefore think that mitoxantrone pharmacokinetics is generallv best described by an open
3-compartment model. Clearance values showed that there was no saturation in mitoxantrone elimination.
es-en at the highest doses. Terminal elimination half-life was probably underestimated because of the lack of
late time-points in some kinetics. The half-life is long for patients receiving high-dose mitoxantrone (mean
salue u-as 50 h) and it u-ould be hazardous to perform BMT too earlv after mitoxantrone infusion.
Mitoxantrone metabolites u-ere detected in the plasma of fixe patients receiving high-dose mitoxantrone and in
one with hepatic impairment.
The anthracenedione drug. mitoxantrone (Novantronez). is a
svnthetic analogue of anthracyclines which is active in the
treatment of leukaemia. 1 mphoma. breast cancer and ovar-
ian cancer (Smith. 1983: Zee-Cheng & Cheng. 1983: Shenken-
berg & Von Hoff. 1986: Lenk et al.. 1987). Its mechanism of
action involves DNA intercalation, and inhibition of topoiso-
merase II activity. The involvement of mitoxantrone in multi-
drug resistance remains unclear and its cross resistance with
doxorubicin (adriamycin) is only partial. Moreover. its toxic
side effects are weaker than those of doxorubicin. In partic-
ular. the cardiotoxicitv of mitoxantrone is much less pro-
nounced. alloWing the use of a relatively higher dosage than
that of anthracyclines. However, the haematologic toxicity of
mitoxantrone is severe. The drug therefore seemed to be a
good candidate for high-dose chemotherapy because of the
possibility of associating an intercalating agent with the
alkylating drugs. cyclosphosphamide and melphalan. Autolo-
gous bone marrow transplantation (ABMT) was associated
to prevent haematologic toxicity.
Mitoxantrone pharmacokinetics have been described in
different studies with conventional dosages (10-12 mgm -)
by either an open two- (Reynolds. et al.. 1981: Savaraj et al..
1982a; 1982b; Larson et al.. 1987) or an open three-compart-
ment model (Hulhoven et al.. 1984; Ehninger et al.. 1985a:
1986: Smyth et al.. 1986: Wilkinson et al.. 1986): in some
studies it has been described with both models (Alberts et al..
1983; 1985a; 1985b; van Belle et al.. 1986). Besides the large
interpatient variability described by all these authors. the
pharmacokinetic parameters were very different from one
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studv to another. Thus it seemed difficult to define schedules
of drug administration in new protocols. such as intravenous
(i.v.) infusion of high dosages. We decided to make a phar-
macokinetic study in this situation in order to determine if (i)
the elimination of the drug was saturable. (ii) the residual
plasma concentrations were acceptable before performing the
BMT.
A phase I-II clinical trial using high-dose mitoxantrone
was initiated in the BMT unit of Paoli-Calmettes Institute
(Maraninchi et al.. 1987: Viens et al.. 1990). The aim of this
trial was to evaluate the clinical effects of increasing doses of
mitoxantrone administered in association with a regimen of
high-dose chemotherapy with alkylating agents. cyclophos-
phamide and melphalan. The pharmacokinetic evaluation of
mitoxantrone presented in this paper was simultaneously
conducted in these patients.
Materials and methods
We first studied the pharmacokinetics of mitoxantrone as a
single agent at the conventional dosage to obtain the basic
pharmacokinetic data used as our reference data (patient
group I). Patients receiving the high-dose regimen were
identified as the group II.
The experimental conditions were identical for both
groups. Finally a comparison of these standard data with
those obtained with the high-dose regimen was performed.
Patients
Fifteen women aged from 16 to 63 years were entered in the
study. They had histologically proved malignancies refractory
to usual therapies. Patients with a history of heart disease
were excluded. Nine patients had metastatic breast cancer.
three had inflammatory breast cancer. two had refractory
ovarian cancer. and one had rhinopharyngeal carcinoma.
Details are reported in Table I and II.
Upon entry in this study. patients receiving the single drug
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Table I Clinical data of patient group I
12 mg m ')
(consventional dose:
Site of Total dose
Patients .4ge cancer (mg)
A 37 Breast 17
B la 62 Breast 17
17
5 17
C 42 Breast 17
D 52 Ovarn 18
E 62 Breast 17
F 42 Breast 14
G 63 Breast 15
H 46 Breast 18
aFirst second and fifth courses.
Table n Clinical data of patient group II (high-dose
mitoxantrone + autologous bone marrow transplantation)
Dose Total dose
Patients Age Disease (mg m (mg)
1 16 Rhinopharvnx 12 17
carcinoma
2'5 Inflammatorn 1' x 3 17 x 3
breast cancer (36) (51)
3 49 Breast cancer 30 50
4 27 Inflammatorv 33 50
breast cancer
5 40 Ovarian cancer 40 60
6 44 Inflammatorn 40 60
breast cancer
7 43 Breast cancer 40 60
had a life expectancy of more than 1 month. and the others
of more than 3 months.
The investigations before treatment included complete
blood cell count. standard serum biochemistry (with renal
and hepatic function tests), X-ray chest examination, specific
tumour examination (tomodensitometry. echography. radio-
nucleide examinations). All patients had normal kidney and
liver functions: they also had correct cardiac function eval-
uated by ECG and radionucleide ventricular ejection frac-
tion. Other investigations were performed if appropriate.
Chemotherapy
Mitoxantrone was administered by i.v. infusion with a per-
ipheral blood access for the conventional dose. or through a
double central venous catheter for the high-dose treatment.
Mitoxantrone was provided by Lederle Laboratonres (Rungis.
France) and was dissolved in 100 ml of 0.9% NaCl solution
or 5% dextrose solution. The infusion rate was constant and
controlled by an electric pump.
For the conventional dose. the administration protocol was
12mgm-- every 21 days which corresponds to a total dose
of 14-18 mg in a 10-min infusion (patient group I) except for
patient B who received the second course 7 days after the
first one. For the high-dose protocol (group II), day 0 was
the day of the ABMT. Mitoxantrone was administered at the
dose of 12 mg m day-' in a 10-min infusion on day -7 for
patient 1, and on day -9, day -8 and day -7 for patient 2
(see Table II). For the remaining patients in group II, mitox-
antrone was administered on day -7 in a single 1-h infusion
at increasing doses, i.e. 30. 33, 40 mg m- (total dose of 45,
50 and 60 mg for the tested patients). Mitoxantrone was
associated with the other anti-cancer drugs usually used in
the BMT unit for high-dose chemotherapy: cyclophos-
phamide at the dose of 60 mg kg-' day-', on days -5 and
day -4, and melphalan: 140mgm-2 day-', on day -2.
For the patients of group II, other medications consisted
of oral antibioprophylaxis with unabsorbed drugs (cepha-
mandole, colistin, amphotericin, tobramycin) and of an anti-
emetic drug (chlorpromazine, 20-30 mg daily).
Pharmacokinetic stud}
Sampling Blood samples (15 to 18 samples) were collected
from a central venous catheter in heparinized polypropylene
tubes at different times:
- for the standard dose infusions (10-min duration). blood
was obtained before the infusion (70). and 8. 13. 20. 30.
40 min. 1. 2. 3. 4. 6. 12. 24. 36 and 48 h after the beginning
of the infusion:
for the high-dose regimen: before the infusion. at the end
of the infusion. and 20. 40 min. 1. 2. 4. 6. 12. 18. 24. 36 and
48 h after the end of the infusion: and daily until day 0.
Blood samples were of 5 or 10 ml. They were immediatelv
centrifuged at 1000 x g for 10 min. Plasma was separated
and collected in polypropylene tubes containing 1 mg of
ascorbic acid used as antioxidant. Tubes were vortexed for
30 s and stored at - 20C until analI sis. For patient B.
samples were drawn during the 1st. the 2nd and the 5th
courses.
Analisis Plasma mitoxantrone concentrations were mea-
sured with a high-performance liquid chromatography (HP-
LC) assay previously described bv Payet et al. (1988) and
slightly modified to obtain a higher sensitivity (Catalin et al..
1988). This technique allowed separation of both mitoxan-
trone and its two major metabolites (mono- and dicarboxylic
acid derivatives) in various biological fluids. and plasma
quantitation of mitoxantrone (Figure 1). Metabolites were
identified according to their retention time compared with
those of standards provided by Lederle Laboratories.
To inject a larger amount of plasma without clogging the
HPLC system. plasma proteins were precipitated with a
mixture of 300 sulphosalicyclic acid-methanol (50-50°0).
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Figre I Upper: chromatogram of a blank plasma enriched with
25 ng of mitoxantrone and With 100 mg of internal standard.
Lower: plasma chromatogram of patient 5 after a I h infusion of
60 m, of mitoxantrone. The sample was obtained 2 h after the
end of the infusion. M = mitoxantrone; IS = internal standard;
( = dicarboxylic acid denrvative; (0 = monocarboxylic acid der-
ivative.
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CL 236143. provided by Lederle Laboratories. was used as
internal standard and was added to plasma before protein
precipitation. It allowed quantification of mitoxantrone con-
centrations according to the internal standard method.
Plasma samples were injected on an enrichment precolumn
which specifically retained CL 236143. mitoxantrone and or
its metabolites. the washing phase was methanol-water
(5-95%). The specific molecules were then eluted on an
analytical column (C18 Nuceosil. jm, Waters Associates)
with ammonium formate buffer (1.6 M; pH 4.0)-acetonitrile-
water (50-20-30%) at a flow rate of 1.3 ml min-'. detection
was performed in the visible at 655 nm.
The detection limit of unchanged mitoxantrone in plasma
was 0.5 ngml-1.
Since the two main metabolites were not available in large
amounts as standards. they were assayed in mitoxantrone
equivalents as performed by others (Ehninger et al.. 1985a;
1985b; 1986). Metabolite peaks detected at 655 nm were
compared with those of unchanged drug to allow interassay
comparison of both metabolites.
Pharmacokinetics Plasma concentration-time curves for each
patient were subjected to pharmacokinetic analyses using the
APIS software (Iliadis et al.. 1988). All plasma kinetics were
identified with an open two- and an open three-compartment
model and the pharmacokinetic parameters were computed:
the adequate model was chosen by using an F-test.
When mitoxantrone was not detectable at 10. its plasma
level was considered as zero. and thus the kinetics were
modelled independently from any previous one. For patient
B. both the first plasma concentration-time curve, and the
first two courses separated by 7 days were modelled succes-
sively. whereas the last course (the fifth one). which had an
undetectable TD value. was modelled alone. In group II. the
three close infusions of patient 2 were identified all together.
Comparison of the pharmacokinetic parameters of differ-
ent groups was performed with a Student's t-test. Means
were considered significantly different when P<0.05.
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Figure 2 Plasma pharmacokinetics of mitoxantrone and its
metabolites in patient 5 after a 60 mg mitoxantrone infusion in
I h. Graph of plasma mitoxantrone and metabolite concentra-
tions. 0 = unchanged mitoxantrone; A = monocarboxylic acid
derivative; A = dicarboxvlic acid denrvative.
Pharmacokinetic parameters
Results of individual pharmacokinetic parameters are pres-
ented in Table III.
Conventional dose For patient B. as the TO of the second
course was 13.05 ng ml- . this course was modelled with the
first one. In group I. plasma concentration-time curves were
best described by either an open two-compartment model for
half of the patients or an open three-compartment model for
the others (Figure 3). The mean total plasma clearance (CL)
was 21.41 ± 14.59 1hi; values ranged between 5.85 and
54.65 1h-'. The mean apparent terminal half-life value (Tj)
Results
Analy tical assay
Mitoxantrone was exclusively assaved in patient plasma. In
some patients receiving high-dose mitoxantrone and in one
patient receiNing a standard dose. unchanged mitoxantrone
and its mono- and dicarboxylic acid derivatives could be
quantified. This was performed in patient 5 (Figure 1) and to
a lesser extent in patients 2. 3. 4. 7 and A during a few hours
after drug infusion.
Plasma concentration-time curves
The maximum mitoxantrone concentrations detected in plas-
ma ranged between 673 and 2461 ng ml-' for patients re-
ceiving the conventional dosage. and between 1473 and
2687 ng ml-' for those receiving high-dose mitoxantrone in a
1 h infusion. Mitoxantrone could be detected no later than
the 12' h in certain patients of group I. and until the 8' day
after the infusion of a high dose of drug.
The highest concentration of metabolites was reached
40 mmn to 2 h after the end of the infusion (Figure 2). The
concentration of these metabolites estimated in mitoxantrone
equivalents was much lower than that of unchanged drug. In
patient 5. the monocarboxylic acid derivative reached 25.2
mitoxantrone equivalents 40 mn after the end of infusion
whereas the dicarboxylic acid derivative reached 27.24 mitox-
antrone equivalents 2 h after the end of the infusion. Meta-
bolites rapidly disappeared from plasma and they could not
be quantified after the first day because of their low plasma
concentrations.
Table 111 Individual pharmacokinetic parameters
No. CL 7i Ut .4 AUC
Patients compartments (Ih h I (fig h ml-'
Group I
A 3 7.91 19.61 119.04 2.15
B1 2 16.31 8.05 99.99 1.04
2a t 19.94 9.76 152.40 0.85
>3 30.47 8.13 88.73 0.56
C 2 12.65 4.49 46.59 1.34
D 2 6.27 28.21 188.33 2.87
E 3 25.87 21.71 233.02 0.66
F 3 5.85 84.22 517.91 2.39
G 2 54.65 5.95 122.73 0.27
H 3 34.23 8.15 90.20 0.52
Mean 21.41 19.83 165.89 1.26
± s.d. + 14.59 ± 23.95 ± 134.75 ± 0.90
Group II
1 3 15.08 26.39 320.94 1.13 2b r 13.04 29.94 276.37 3.91
3 3 25.37 84.19 543.28 1.97
4 3 25.38 61.21 366.78 1.97
5 3 14.77 64.03 263.98 3.12
6 3 32.02 41.73 801.74 1.87
7 3 26.08 44.35 322.81 1.30
Mean 21.68 50.26 413.70
± s.d ± 7.30 ± 20.62 ± 194.81
Mean 21.52 32.36 267.93
± s.d. ± 12.37 ± 26.84 ± 200.62
'First plus second courses together; bFirst plus second plus third
courses together. CL = total plasma clearance: 71= apparent terminal
half-life; Vt = total distribution volume: AUC = area under the curve.
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Figure 3 Plasma pharmacokinetics of patient H after a 18 mg
mitoxantrone 10 min infusion. Computer-fitted curve of mitoxan-
trone plasma concentrations. Kinetics was identified with an open
three-compartment model.
was 19.83 ± 23.95 h (range: 4.49-84.22). The mean total dis-
tnbution volume (Vt) was 165.89 ± 134.75 1 (range:
46.59-517.91). and the mean area under the curve (AUC)
was 1.26±0.90pghml-l (range: 0.27-2.87).
It is of interest to examine discrepancies in the pharm-
acokinetic parameters of the open two- and three-compart-
ment models. With an open two-compartment model mean
TI was 11.29±9.67h. mean CL was 21.96± 18.961h-' and
mean Vt was 122.01 ± 53.61 1; for the kinetics best descnrbed
with an open three-compartment model, these values were
28.36 31.85 h. 20.87 ± 13.33 1 h-' and 209.78 ± 182.12 1 re-
spectively.
High dose In group II. all kinetics but one were best
identified with an open three-compartment model (Figure 4).
The CL ranged between 13.04 and 32.021h-'. with a mean
value of 21.68 ± 7.30 1 h-'. The mean T7 was 50.26 20.62 h
(26.39-84.19). The mean Vt was 413.70 194.81 1
(263.98-801.74). The mean AUC was not calculated because
the amount of infused drug was not identical for each
patient. Values varied from 1.13 to 3.91 fighmln .
Discussion
In this work we studied mitoxantrone pharmacokinetics in
routine clinical situations; this explains some modifications in
the initial protocol.
Anal)ysis ofclearance
Despite the great interindividual variability in CL. in the first
group of patients. mean CL of open two- or three-com-
partment model kinetics were not significantly different.
Mean CL for groups I and II are not significantly different as
verified with a t-test; hence there was no decrease in CL with
increasing infused dosages and we conclude that there is no
saturation in mitoxantrone elimination at the doses used.
even at the highest ones (3.5-fold higher than usual). This
observation represents a pharmacokinetic argument to con-
sider mitoxantrone as a good candidate for high-dose chemo-
therapy.
Apparent terminal elimination phase half-life
In the first group of patients, there was no significant
difference between mean Ti of kinetics identified with an
open two- or with an open three-compartment model.
In the second group of patients, who received the highest
doses, the determination of the TI was more reliable than in
the first group. Moreover, in group II, mean TI was longer
than that reported for the first group and the difference
Fire 4 Plasma pharmacokinetics of mitoxantrone in patient 7
after I h infusion of 60 mg of mitoxantrone. Computer-fitted
curve of mitoxantrone plasma concentrations. Kinetics was iden-
tified with an open three-compartment model.
between these mean values was significant (P<0.02). The
precision of TI reported was made possible by the sensitivity
of the HPLC assay used and by the large number of plasma
mitoxantrone determinations during 8 days (Launay et al..
1989). These data suggest that the 'true' half-life of mitoxan-
trone is much longer than that determined with the open
two-compartment model. generally about 30-60 h according
to others (Mulder et al.. 1989).
The determination of a long VI (50.26 ± 20.62 h). and the
detection of plasma mitoxantrone concentrations of about
1 ng ml' up to 7 days after a high-dose protocol are verv
important in the case of BMT. In vitro mitoxantrone LDio
for granulocyte-macrophage progenitor cells (CFU-GM) has
been described as about 10 ng ml-' for a 6-h incubation, and
about 2.5 ng ml1 for a 7-day incubation (Fountzillas et al..
1986). These concentrations are higher than those detected at
day 0 (range: 0.6- 1.0 ng ml-'). In our series. no patient had
a delayed haematopoietic recovery. Indeed. it would be
hazardous to perform the transplantation too early after
mitoxantrone infusion.
Interindividual variability
In patient group I, the kinetics were identified with an open
two- or an open three-compartment model, but in the second
group all patients but one were identified with an open
three-compartment model. This intenrndividual vanrability
could at least in part be explained by the undetectable mi-
toxantrone plasma concentrations in late samples (under
0.5 ng ml-') for some patients or the small number of late
samples. For the kinetics of group I patients. determination
of mitoxantrone plasma concentrations was sometimes im-
possible after the 12' h. Hence the latest concentration-time
points of the third elimination phase could not be determined
and kinetics were best identified with an open two-compart-
ment model.
In both groups of patients, however. we observed a
great interindividual variability in pharmacokinetic para-
meters (CL. TI, Vt). This observation is in complete agree-
ment with that of other authors (Savaraj et al.. 1982a;
Alberts et al.. 1985a; Ehninger et al.. 1986; Mulder et al..
1989).
The case of patient A is remarkable in group I. This
woman with a marked hepatic impairment due to metastases
had the highest plasma mitoxantrone concentration of group
I, probably because of deficient hepatic elimination.
Metabolites
It is now well known that mitoxantrone is metabolized into
two main metabolites identified as the mono- and the dicar-
IlWU
100
10
1'(
E C
0
C
._
C
c
0
c 0
0.
1
I n.tw
--rPHARMACOKINETICS OF MITOXANTRONE 403
boxylic acid derivatives, and into a group of unidentified
metabolites which are more polar than the other ones (Chic-
carelli et al., 1986: Richard et al., 1991). The first two seem
to be inactive on murine leukaemia P388 (Chiccarelli et al.,
1986). These metabolites were most often descnrbed in the
urine of patients (Ehninger et al., 1985a; 1985b; 1986; Chic-
carelli et al., 1986) and by Ehninger et al. in plasma (1985a;
1985b; 1986) in a single patient after a 14mgm-' mitoxan-
trone infusion. As others. we did not observe plasma meta-
bolites in most patients receiving conventional drug dosage:
but we did in four of five patients who received more than
30 mg m of mitoxantrone in a 1 h infusion (patients 3. 4. 5.
7). in the patient receiving three daily doses of 12 mg m-
(patient 2). and in one patient in group I who had a severe
hepatic impairment (patient A).
Since the liver is the major organ of mitoxantrone uptake
(Alberts et al.. 1983: 1985b; Roboz et al.. 1984: Stewart et al..
1986). and since human hepatocytes in vitro produce a
significant amount of metabolites (Richard et al.. 1991) it is
highly likely that metabolites are produced mainly by the
liver in humans.
The presence of metabolites in patient A may be due to the
fact that her mitoxantrone plasma levels were higher than
those of other patients of this group or because their excre-
tion was lowered. In the other patients. there is no saturation
of mitoxantrone elimination. We also know that its in vitro
biotransformation by hepatocytes is not saturable even at
very high concentrations (10jig ml-) (Richard et al.. 1991);
hence this phenomenon is certainly only connected with
higher mitoxantrone plasma concentrations. These observa-
tions further demonstrate the role of the liver in both drug
metabolism and elimination in vivo.
Conclusion
This work (i) confirms the large interpatient variability. even
in the high-dose group which was more homogeneous. Be-
sides, it shows (ii) that there is no saturation in mitoxantrone
elimination in patients receiving 60 mg, (iii) that terminal
plasma half-life is generally long (30-60 h). and (iv) that
plasma metabolites are frequently observed in patients receiv-
ing high-dose infusions. With regard to pharmacokinetic
data, mitoxantrone can be used in high-dose chemotherapv
before bone marrow transplantation. Moreover. because of
the long elimination half-life of mitoxantrone. a 1-week
decay between the last drug infusion and the transplantation
has to be respected.
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